Symbols / LIXT $3.05 -0.49% Lixte Biotechnology Holdings, Inc.
LIXT Chart
About
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 26.54M |
| Enterprise Value | 34.39M | Income | -6.08M | Sales | — |
| Book/sh | 0.90 | Cash/sh | 0.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 3.38 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 3.83 |
| Current Ratio | 3.88 | Debt/Eq | 9.44 | LT Debt/Eq | — |
| EPS (ttm) | -1.26 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -46.00% |
| ROE | -101.95% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.70M |
| Shs Float | 11.60M | Short Float | 0.64% | Short Ratio | 1.89 |
| Short Interest | — | 52W High | 6.26 | 52W Low | 0.64 |
| Beta | — | Avg Volume | 65.58K | Volume | 21.82K |
| Target Price | — | Recom | None | Prev Close | $3.06 |
| Price | $3.05 | Change | -0.49% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.05
Latest analyst target
3. DCF / Fair value
$-5.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.05
Low
—
High
—
Mean
—
- Cancer drug study doubles to 42 patients after LIXTE's $11M raise - Stock Titan ue, 31 Mar 2026 19
- LIXT 8-K & SEC Filings - Yahoo Finance - Yahoo! Finance Canada Sat, 04 Apr 2026 03
- LIXT Technical Analysis & Stock Price Forecast - Intellectia AI hu, 02 Apr 2026 07
- Lixte Biotechnology (NASDAQ: LIXT) posts larger loss and flags going-concern risk - Stock Titan ue, 31 Mar 2026 19
- Lixte Amends Share Exchange, Clarifies Liora Ownership Structure - tipranks.com ue, 10 Mar 2026 07
- Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming - The Globe and Mail Wed, 25 Mar 2026 07
- Lixte Biotechnology shareholders approve board nominees and stock plan amendment - Investing.com hu, 11 Dec 2025 08
- LIXTE Biotechnology’s Expanded Trial Could Be Its Best Shot at Breaking the Stagnation - Bitget ue, 31 Mar 2026 04
- Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely? - Yahoo Finance Wed, 19 Nov 2025 08
- LIXT: Is a Growth Surge on the Horizon? - timothysykes.com hu, 03 Jul 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 27 Mar 2024 14
- LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI Sat, 04 Apr 2026 09
- LIXTE (NASDAQ:LIXT) widens oncology platform with proton therapy buy and $2.6M digital assets - Stock Titan Wed, 03 Dec 2025 08
- Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership - The Globe and Mail Fri, 27 Mar 2026 15
- Lixte Biotechnology Holdings, Inc. (LIXT) stock price, news, quote and history - Yahoo Finance Australia hu, 28 Aug 2025 00
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
5.11
+42.96%
|
3.57
-29.81%
|
5.09
-19.35%
|
6.31
|
| Research And Development |
|
0.25
-64.90%
|
0.73
-19.14%
|
0.90
-33.44%
|
1.35
|
| Selling General And Administration |
|
4.85
+70.48%
|
2.85
-32.10%
|
4.19
-15.52%
|
4.96
|
| General And Administrative Expense |
|
4.85
+70.48%
|
2.85
-32.10%
|
4.19
-15.52%
|
4.96
|
| Salaries And Wages |
|
2.14
+82.68%
|
1.17
-31.81%
|
1.72
-32.56%
|
2.55
|
| Other Gand A |
|
2.46
+97.90%
|
1.24
-38.92%
|
2.03
-15.89%
|
2.41
|
| Other Operating Expenses |
|
—
|
—
|
—
|
1.15
|
| Total Expenses |
|
5.11
+42.96%
|
3.57
-29.81%
|
5.09
-19.35%
|
6.31
|
| Operating Income |
|
-5.11
-42.96%
|
-3.57
+29.81%
|
-5.09
+19.35%
|
-6.31
|
| Total Operating Income As Reported |
|
-5.11
-42.96%
|
-3.57
+29.81%
|
-5.09
+19.35%
|
-6.31
|
| EBITDA |
|
-6.00
-68.12%
|
-3.57
+29.61%
|
-5.07
+19.56%
|
-6.30
|
| Normalized EBITDA |
|
-5.10
-42.93%
|
-3.57
+29.71%
|
-5.07
+19.48%
|
-6.30
|
| EBIT |
|
-6.00
-68.12%
|
-3.57
+29.61%
|
-5.07
+19.56%
|
-6.30
|
| Total Unusual Items |
|
-0.90
-26460.95%
|
-0.00
-274.16%
|
0.00
+157.91%
|
-0.00
|
| Total Unusual Items Excluding Goodwill |
|
-0.90
-26460.95%
|
-0.00
-274.16%
|
0.00
+157.91%
|
-0.00
|
| Net Income |
|
-6.01
-67.58%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Pretax Income |
|
-6.01
-67.58%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Net Non Operating Interest Income Expense |
|
-0.00
+81.89%
|
-0.01
-879.97%
|
0.00
-45.99%
|
0.00
|
| Interest Expense Non Operating |
|
0.01
-45.56%
|
0.02
+3.62%
|
0.02
+82.91%
|
0.01
|
| Net Interest Income |
|
-0.00
+81.89%
|
-0.01
-879.97%
|
0.00
-45.99%
|
0.00
|
| Interest Expense |
|
0.01
-45.56%
|
0.02
+3.62%
|
0.02
+82.91%
|
0.01
|
| Interest Income Non Operating |
|
0.01
+4.82%
|
0.01
-59.69%
|
0.02
+56.19%
|
0.01
|
| Interest Income |
|
0.01
+4.82%
|
0.01
-59.69%
|
0.02
+56.19%
|
0.01
|
| Other Income Expense |
|
-0.90
-26351.04%
|
-0.00
-274.16%
|
0.00
+157.91%
|
-0.00
|
| Other Non Operating Income Expenses |
|
0.00
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.90
-26460.95%
|
-0.00
-274.16%
|
0.00
+157.91%
|
-0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-6.01
-67.58%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Net Income From Continuing Operation Net Minority Interest |
|
-6.01
-67.58%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Net Income From Continuing And Discontinued Operation |
|
-6.01
-67.58%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Net Income Continuous Operations |
|
-6.01
-67.58%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Minority Interests |
|
0.00
|
0.00
|
—
|
—
|
| Normalized Income |
|
-5.11
-42.51%
|
-3.58
+29.60%
|
-5.09
+19.34%
|
-6.31
|
| Net Income Common Stockholders |
|
-6.08
-69.51%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Diluted EPS |
|
-1.26
+20.75%
|
-1.59
+40.23%
|
-2.66
+33.33%
|
-3.99
|
| Basic EPS |
|
-1.26
+20.75%
|
-1.59
+40.23%
|
-2.66
+33.33%
|
-3.99
|
| Basic Average Shares |
|
4.84
+115.21%
|
2.25
+17.41%
|
1.92
+21.10%
|
1.58
|
| Diluted Average Shares |
|
4.84
+115.21%
|
2.25
+17.41%
|
1.92
+21.10%
|
1.58
|
| Diluted NI Availto Com Stockholders |
|
-6.08
-69.51%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Insurance And Claims |
|
0.26
-40.73%
|
0.43
-1.93%
|
0.44
|
—
|
| Preferred Stock Dividends |
|
0.07
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
12.73
+1011.62%
|
1.15
-73.41%
|
4.31
-22.52%
|
5.56
|
| Current Assets |
|
5.18
+352.06%
|
1.15
-73.41%
|
4.31
-22.52%
|
5.56
|
| Cash Cash Equivalents And Short Term Investments |
|
5.11
+391.54%
|
1.04
-75.28%
|
4.20
-21.48%
|
5.35
|
| Cash And Cash Equivalents |
|
5.11
+391.54%
|
1.04
-75.28%
|
4.20
-21.48%
|
5.35
|
| Cash Financial |
|
5.11
+391.54%
|
1.04
-75.28%
|
4.20
-21.48%
|
5.35
|
| Prepaid Assets |
|
0.07
-32.89%
|
0.11
+1.35%
|
0.11
-49.36%
|
0.21
|
| Other Current Assets |
|
—
|
—
|
—
|
0.01
|
| Total Non Current Assets |
|
7.56
|
0.00
|
0.00
|
0.00
|
| Net PPE |
|
7.56
|
0.00
|
—
|
—
|
| Gross PPE |
|
7.56
|
0.00
|
—
|
—
|
| Other Properties |
|
7.56
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
1.77
+456.76%
|
0.32
+1.41%
|
0.31
-20.69%
|
0.40
|
| Current Liabilities |
|
1.33
+318.84%
|
0.32
+1.41%
|
0.31
-20.69%
|
0.40
|
| Payables And Accrued Expenses |
|
0.44
+424.58%
|
0.08
-46.92%
|
0.16
-32.06%
|
0.23
|
| Payables |
|
—
|
—
|
0.16
-32.06%
|
0.23
|
| Accounts Payable |
|
—
|
—
|
0.12
-34.42%
|
0.18
|
| Current Debt And Capital Lease Obligation |
|
0.66
|
—
|
—
|
—
|
| Current Debt |
|
0.07
|
—
|
—
|
—
|
| Other Current Borrowings |
|
0.07
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.60
|
0.00
|
—
|
—
|
| Current Deferred Liabilities |
|
0.23
-1.25%
|
0.24
+49.64%
|
0.16
-4.80%
|
0.17
|
| Current Deferred Revenue |
|
0.23
-1.25%
|
0.24
+49.64%
|
0.16
-4.80%
|
0.17
|
| Total Non Current Liabilities Net Minority Interest |
|
0.44
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
9.66
+1068.26%
|
0.83
-79.29%
|
3.99
-22.66%
|
5.17
|
| Common Stock Equity |
|
7.93
+396.79%
|
-2.67
-640.22%
|
0.49
-70.29%
|
1.67
|
| Capital Stock |
|
1.73
-50.50%
|
3.50
+0.00%
|
3.50
+0.00%
|
3.50
|
| Common Stock |
|
0.00
+290.67%
|
0.00
+0.00%
|
0.00
+35.54%
|
0.00
|
| Preferred Stock |
|
1.73
-50.53%
|
3.50
+0.00%
|
3.50
+0.00%
|
3.50
|
| Share Issued |
|
8.70
+286.93%
|
2.25
+0.00%
|
2.25
+35.12%
|
1.66
|
| Ordinary Shares Number |
|
8.70
+286.93%
|
2.25
+0.00%
|
2.25
+35.12%
|
1.66
|
| Additional Paid In Capital |
|
66.01
+33.64%
|
49.39
+0.85%
|
48.98
+8.69%
|
45.06
|
| Retained Earnings |
|
-58.08
-11.54%
|
-52.07
-7.40%
|
-48.48
-11.72%
|
-43.39
|
| Minority Interest |
|
1.30
|
0.00
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
10.96
+1225.11%
|
0.83
-79.29%
|
3.99
-22.66%
|
5.17
|
| Total Capitalization |
|
9.66
+1068.26%
|
0.83
-79.29%
|
3.99
-22.66%
|
5.17
|
| Working Capital |
|
3.85
+364.84%
|
0.83
-79.29%
|
3.99
-22.66%
|
5.17
|
| Invested Capital |
|
8.00
+399.37%
|
-2.67
-640.22%
|
0.49
-70.29%
|
1.67
|
| Total Debt |
|
0.66
|
0.00
|
—
|
—
|
| Capital Lease Obligations |
|
0.60
|
0.00
|
—
|
—
|
| Net Tangible Assets |
|
9.66
+1068.26%
|
0.83
-79.29%
|
3.99
-22.66%
|
5.17
|
| Tangible Book Value |
|
7.93
+396.79%
|
-2.67
-640.22%
|
0.49
-70.29%
|
1.67
|
| Dueto Related Parties Current |
|
—
|
—
|
0.04
-22.84%
|
0.05
|
| Preferred Stock Equity |
|
1.73
-50.53%
|
3.50
+0.00%
|
3.50
+0.00%
|
3.50
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.07
+2.97%
|
-3.16
+26.29%
|
-4.29
+6.91%
|
-4.61
|
| Cash Flow From Continuing Operating Activities |
|
-3.07
+2.97%
|
-3.16
+26.29%
|
-4.29
+6.91%
|
-4.61
|
| Net Income From Continuing Operations |
|
-6.01
-67.58%
|
-3.59
+29.51%
|
-5.09
+19.41%
|
-6.31
|
| Other Non Cash Items |
|
0.06
|
—
|
—
|
—
|
| Stock Based Compensation |
|
1.56
+272.81%
|
0.42
-45.88%
|
0.77
-49.99%
|
1.55
|
| Operating Gains Losses |
|
0.90
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
0.90
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.41
+13630.63%
|
0.00
-85.38%
|
0.02
-86.71%
|
0.15
|
| Change In Receivables |
|
—
|
—
|
—
|
—
|
| Change In Prepaid Assets |
|
0.04
+2569.63%
|
-0.00
-101.38%
|
0.10
+59.15%
|
0.06
|
| Change In Payables And Accrued Expense |
|
0.38
+617.70%
|
-0.07
+0.57%
|
-0.07
-3291.37%
|
0.00
|
| Change In Payable |
|
—
|
—
|
—
|
—
|
| Change In Account Payable |
|
—
|
—
|
—
|
—
|
| Change In Other Working Capital |
|
-0.00
-103.77%
|
0.08
+1084.32%
|
-0.01
-109.00%
|
0.09
|
| Investing Cash Flow |
|
-3.17
|
0.00
|
—
|
—
|
| Cash Flow From Continuing Investing Activities |
|
-3.17
|
0.00
|
—
|
—
|
| Net Investment Purchase And Sale |
|
-3.08
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-3.08
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
-0.10
|
—
|
—
|
—
|
| Financing Cash Flow |
|
10.31
|
0.00
-100.00%
|
3.14
-38.86%
|
5.14
|
| Cash Flow From Continuing Financing Activities |
|
10.31
|
0.00
-100.00%
|
3.14
-38.86%
|
5.14
|
| Net Common Stock Issuance |
|
10.27
|
0.00
-100.00%
|
3.14
-38.98%
|
5.14
|
| Proceeds From Stock Option Exercised |
|
0.05
|
0.00
-100.00%
|
0.01
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
4.07
+228.55%
|
-3.16
-175.20%
|
-1.15
-317.11%
|
0.53
|
| Beginning Cash Position |
|
1.04
-75.28%
|
4.20
-21.48%
|
5.35
+10.98%
|
4.82
|
| End Cash Position |
|
5.11
+391.54%
|
1.04
-75.28%
|
4.20
-21.48%
|
5.35
|
| Free Cash Flow |
|
-3.07
+2.97%
|
-3.16
+26.29%
|
-4.29
+6.91%
|
-4.61
|
| Interest Paid Supplemental Data |
|
0.01
-45.56%
|
0.02
+3.62%
|
0.02
+82.91%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
10.27
|
0.00
-100.00%
|
3.14
-38.98%
|
5.14
|
| Issuance Of Capital Stock |
|
10.27
|
0.00
-100.00%
|
3.14
-38.98%
|
5.14
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-20 View
- 8-K2026-03-10 View
- 8-K2026-02-18 View
- 8-K2025-12-31 View
- 42025-12-29 View
- 42025-12-29 View
- 8-K2025-12-23 View
- 8-K2025-12-22 View
- 8-K2025-12-11 View
- 8-K2025-11-25 View
- 10-Q2025-11-12 View
- 8-K2025-09-11 View
- 42025-09-04 View
- 8-K2025-09-04 View
- 8-K2025-08-19 View
- 42025-08-18 View
- 42025-08-18 View
- 8-K2025-08-14 View
- 10-Q2025-08-07 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|